Exjade (ICL 670) : A new oral iron chelator

Journal of Association of Physicians of India

Volumn 54, Issue MAR., 2006, Pages 214-217

  Agarwal, M B ^a  

^a BOMBAY HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; DEFERASIROX; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

AUDIOVISUAL EQUIPMENT; BETA THALASSEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; BENZOIC ACIDS; BETA-THALASSEMIA; HUMANS; IRON CHELATING AGENTS; MODELS, STRUCTURAL; RANDOMIZED CONTROLLED TRIALS; TRIAZOLES;

EID: 33645135115     PISSN: 00045772     EISSN: 00045772     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Galanello R. Iron chelation : New therapies. Semin Hematol 2001;38:73-76.
2. Giardina PJ, Grady RW. Chelation therapy in β-thalassaemia : The optimistic update. Semin Hematol 2001;38:360-6.
3. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload : Hematology : 2001;47-61.
4. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload : Blood : 2003 (First edition paper, pre-published online March 13).
5. Kontoghiorghes GJ, Agarwal MB, Tondury P, et al. Future of oral iron chelator deferiprone (LI). ICOC Committee. Lancet 1993;341:1479-80.
6. Kontoghiorghes GJ, Agarwal MB, Grady RW, et al. Deferiprone for thalassaemia. Lancet 2000;356:428-29.
7. Kontoghiorghes GJ, Agarwal MB, Tondury P, et al. Deferiprone or fatal iron toxic effects? Lancet 2001;17:882-3.
8. Agarwal MB, Gupte SS, Varandani D, et al. Efficacy and safety of 1-2,dimethyl-3-hydroxypyride-4-one (LI) as an oral iron chelator in patients of β-thalassaemia major with iron overload. J Assoc Phys Ind 1991:39:669-72.
9. Agarwal MB, Gupte SS, Vishwanath C, et al. Long-term assessment of efficacy and safety of LI, an oral iron chelator, in transfusion dependent thalassaemia : Indian trial. Br J Haematol 1992;82:460-466.
10. Agarwal MB. Oral iron chelation : A review with special emphasis on Indian work on deferiprone (LI). Ind J Pediatr 1993;60:509-16.
11. Agarwal MB. LI arthropathy syndrome. J Assoc Physicians India 1994;42:929-30.
12. Agarwal MB. Oral iron chelators. Ind Pediatr 1995;32: 847-51.
13. Ponka P, Borova J, Neuwirth J, Fuchs O, Necas E. A study of intracellular iron metabolism using Pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 1979; 586:278-297.
14. Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs : Potential orally effective iron chelating agents for the treatment of iron overload disease. J Lab Clin Med 1998; 131:306-314.
15. Becker E, Richardson DR. Development of novel aroylhydrazone ligands for iron chelation therapy. 2pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin Med 1999; 134:510-521.
16. Hershko C, Grady RW, Link G. Phenolic ethylenediamine derivatives : A study of orally effective iron chelators. J Lab Clin Med 1984; 103:337-346.
17. Grady RW, Salbe AD, Hilgartner MW, Giardina PJ. Results from a phase I clinical trial of HBED. Adv Exper Med Biol 1994; 356:351-359.
18. Grady RW, Giardina PJ. Oral iron chelators : A potential role for HBED in combination therapy (Abstract Blood 1999;94:3293a).
19. Schnebli HP. CGP 72 670, a new potent, orally active iron chelator (abstract). ISH-EHA Combined Haematology Congress, Amsterdam. The Netherlands. Br J Haematol 1998;102:O-1121a.
20. Piga A, Galanello R, Dessi C, et al. A novel oral iron chelator (ICL 670) results of a phase-I single- dose safety study (abstract). Blood 1999;94:3304a.
21. Nick HP, Acklin P, Faller B, et al. ICL 670 : a new potent, orally active iron chelator. In : Bergeron R, Badman D, Brittenham G, eds. Iron chelators : New Development Strategies. Ponte Vedra, FL Saratoga Publishers : 2000:311-331.
22. Hershko C, Konijn AM, Nick HP, et al. ICL 670 : A new synthetic oral chelator : Evaluation in hypertransfused rats with selective radio-iron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001;97:1115-1122.
23. th Annual ASH meeting, Philadelphia, December, 2002.
24. th Annual ASH meeting, Philadelphia, December, 2002
25. (Abstract : Blood : 2002;100:5a).
26. th Annual ASH meeting, Philadelphia, December, 2002.
27. th Annual ASH meeting, Philadelphia, December, 2002
28. th Annual ASH meeting, Philadelphia, December, 2002.
29. Cappellini MD. Iron-chelating therapy with the new oral agent ICL 670 (Exjade). Best Practice and Research Clinical Haematology 2005,18:289-98.
30. Galanello R, Piga A, Alberti D, et al. Safety, tolerability and pharmacokinetics of ICL 670, a new orally active iron chelating agent in patients with transfusion-dependent iron overload due to beta thalassaemia. J Clin Pharmacol 2003;43:565-572.
31. BerlinerN, Rose M. Novel oral chelator ICL 670 is as effective as Deferoxamine in promoting iron elimination in patients with thalassaemia (ASH-online, in press).
32. Nick H, Wong A, Acklin P, et al. ICL 670A : Preclinical profile. In Iron chelation therapy Ed. By Chaim Hershko, Kluwer Academic / Plenum Publishers. 20902:185-203.
33. Porter JB. Monitoring and treatment of iron overload : State of the art and new approaches. Semin Haematol 2005, 42 (No. 2, Suppl 1), 14-18.
34. Hershko C. Treating iron overload : The state of the art. Semin Haematol 2005;42 (No. 2, Suppl 1):2-4.
35. Porter J, Vichinsky E, Rose C, Piga A, et al. A phase II study with ICL 670 (Exjade), a once-daily oral iron chelator. Blood 2004;104:Abstract #193.
36. Wood JC, Otto-Duessel M, Aguilar M, et al. Dose response of deferoxamine, deferiprone and ICL 670 chelation therapy in a Gerbil Model of iron overload. Blood 2004;104:Abstract #3621.
37. Cappellini M, Bejaoul M, Perrotta S, et al. Phase III evaluation of once-daily, oral therapy with ICL 670 (Exjade) versus deferoxamine in patients with beta thalassaemia and Transfusional hemosiderosis. Blood 2004;104:Abstract #3619.
38. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators : from desferrithiocin to ICL 670. Curr Med Chem 2003; 12:1065-76.
39. th National Thalassaemia conference, Delhi, India 2003. PP 26-31.
40. Agarwal MB. ICL 670 : A new oral chelator : A major breakthrough in treatment of thalassaemia. Ind J Hematol and Blood Transfusion 2003, 31 : 26-28.